NuCana (NCNA) shares were up 200% pre-bell Monday after the company said that a combination of NUC-7738 and pembrolizumab led to prolonged progression-free survival in a phase 2 trial for patients with metastatic melanoma.
Dermata Therapeutics (DRMA) stock was over 64% higher following a 6.8% rise in the previous session.
Exicure (XCUR) shares were up 43%, adding to Friday's 5.3% increase.
Agape ATP (ATPC) stock was 26% higher, extending Friday's rally.
Nuvalent (NUVL) shares were up nearly 16% after Friday's 7.1% rise.
Price: 7.6200, Change: +5.08, Percent Change: +200.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments